In 2015 the US FDA has also approved genetically modified chickens that can produce eggs that can treat lysosomal acid lipase
deficiency-a rare genetic condition that prevents the body from breaking down fatty molecules inside cells.
NASDAQ: ALXN) show that 80% of infants (8 out of 10) with rapidly progressive lysosomal acid lipase
deficiency (LAL-D) treated with Kanuma (sebelipase alfa) survived beyond 1 year of age, the company said.
of Castor bean lipid bodies Isolation and Characterization.
2) characterized by lysosomal acid lipase
For instance, Kanuma, which is used for the genetic condition lysosomal acid lipase
deficiency, costs as much as GBP492,000 per patient annually in the UK.
The remaining 38 agents can be classified into the following categories: anticoagulant (2), antidiarrheal (1), antidiabetic (1), antidote (3), antiemetic (1), antifungal (1), antilipemic (2), antineoplastic (13), antipsychotic (2), antiviral (1), bile acid (2), cardiovascular (2), female sexual dysfunction (1), immunomodulator (1), lysosomal acid lipase
deficiency (1), parathyroid hormone (1), pyrimidine analog (1), and respiratory (2).
org, the website for healthcare professionals, has today announced the launch of a new educational resource for lysosomal acid lipase
Patients with Wolman disease have lysosomal acid lipase
deficiency (LAL-D), which results in a fat buildup within the cells of various tissues.
Food and Drug Administration (FDA)'s approval for Kanuma (sebelipase alfa) to treat patients of all ages with a diagnosis of lysosomal acid lipase
Crystal structure of human gastric lipase and model of lysosomal acid lipase
, two lipolytic enzymes of medical interest was reported by (Roussel et al.
Along with displaying the signature Blue Denim Genes Ribbon[TM] associated with The Global Genes Project, Synageva employees will participate in a volunteer fund-raiser with proceeds to benefit the Support Organization for Lysosomal Acid Lipase
Deficiency Advocacy, Care and Expertise (LAL Solace), a patient advocacy group for individuals affected by lysosomal acid lipase
deficiency (LAL Deficiency).
The company's lead programme is SBC-102, which is a recombinant form of the human LAL enzyme being developed as an enzyme replacement therapy for Lysosomal Acid Lipase
Deficiency, a lysosomal storage disorder.